Roadmap to Successful Therapies for Neurodegenerative Diseases
(1) Reardon S, Nature 2018; (2) Pontecorvo MJ, et al., Brain 2019; (3) Gordon BA, et al., Brain 2019 ; (4) Strydom A, et al., Alzheimers Dement (N Y) 2018 ; (5) Lott IT and Head E.,Nat Rev Neurol. 2019; (6) Robinson JL, et al., Brain 2018; (7) Heneka MT et al., Nat Rev Neurosci. 2018; (8) Wang S et al., Int Immunopharmacol. 2019 ; (9) NOD)-like receptor protein 3; (10) Apoptosis-associated speck protein containing a CARD
- Alzheimer’s disease develops because of a complex series of events that take place in the brain over a long period of time.
- Today, Alzheimer’s disease is typically diagnosed once symptoms are already clinically present meaning it is often diagnosed at later stages of the disease where irreversible loss of neurons has already occurred. This may go some way to explaining recent research challenges.
- In response, AC Immune has developed a five point Roadmap to Successful Therapies for Neurodegenerative Diseases. As a strategic leader in the field of neurodegenerative diseases, our Roadmap recognizes the importance of treating earlier, targeting Tau, focusing on more homogeneous populations, precision medicine and exploring neuroinflammation as a target.